The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies
Open accessAbstract
Chemotherapy and targeted therapy are the major treatments for gastric cancer (GC), but drug resistance limits its effectiveness. Here, we profile the proteome of 206 tumor tissues from patients with GC undergoing either chemotherapy or anti-HER2-based therapy. Proteome-based classification reveals four subtypes (G-I-G-IV) related to different clinical and molecular features. MSI-sig high GC patients benefit from docetaxel combination treatment, accompanied by anticancer immune response. Further study reveals patients with high T cell receptor signaling respond to anti-HER2-based therapy; while activation of extracellular matrix/PI3K-AKT pathway impair anti-tumor effect of trastuzumab. We observe CTSE functions as a cell intrinsic enhancer of chemosensitivity of docetaxel, whereas TKTL1 functions as an attenuator. Finally, we develop prognostic models with high accuracy to predict therapeutic response, further validated in an independent validation cohort. This study provides a rich resource for investigating the mechanisms and indicators of chemotherapy and targeted therapy in GC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Proteomic subtyping of the gastric cancer cohort and its association with clinical characteristics. a The heatmap depicts the relative abundance (Z score of FOT) of the signature proteins in four subtypes of 179 GC samples. Biological functions related to these signature proteins are denoted on the right. b The association of four proteomic subtypes with clinical characteristics (including gender, grade, Lauren’s type, primary site, HER2 status, RECIST, and tumor purity, etc.) are annotated with *P-values (two-sided Fisher’s exact test for categorical variables, and two-way ANOVA test for continuous variables). c The Kaplan–Meier curves of overall survival (OS) of each proteomic subtype (G-I, n = 28; G-II, n = 56; G-III, n = 75; and G-IV, n = 20). P-value is calculated by two-sided log rank test. d Left panel: Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of each proteomic subtype. Right panel: Diagram illustrating the differentially expressed signatures and signaling cascades involved in G-I to G-IV. The little heatmap under each protein depicted the Z score of average protein abundance in each proteomic subtype. Red, upregulated proteins; blue, downregulated proteins. e The correlation of the extracellular matrix proteins and different drugs, including 5-FU, OXA, and DOC. The drug sensitivity (half maximal inhibitory concentration [IC50]) of gastric cancer cell lines was from the Cancer Dependency Map Project (DepMap). P-values are derived from two-sided Pearson’s correlation test. f Dose-response curves of MKN45 and MGC803 cell lines overexpressing THSD4 after 72-h treatments with DOC, OXA, and 5FU. Barplots showing the comparison of IC50 values in each group. Bars represent the mean of n = 3 independent experiments with error bars indicating SD. P-values are calculated using two-sided Student’s t test. g Boxplot showing the differential expression of ECM proteins validated by PRM assay (two-sided Wilcoxon rank-sum test, n = 10 biologically independent samples per group). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/57641fdfa2aa40d6bf5a96b5d4d633b9/proteomic-characterization-of-gastric-cancer-response-to-chemotherapy-and-figure-2.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Besides, highly expressed extracellular matrix proteins (THSD4, SRPX2, TGFBI, THBS1, and LAMB2) can serve as indicators to predict drug resistance.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, increased expression of MSI-sig CTSE enhances the effectiveness of DOS therapy but not of XELOX therapy.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“Meanwhile, TKTL1 is negatively associated with the sensitivity of patients to DOS therapy.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“The expression of one of the ECM proteins, THSD4, was closely relevant to worse survival and associated with chemosensitivity (involving 5-FU, oxaliplatin, and docetaxel) in GC cell lines.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“They also found PI3K-AKT signaling pathway had potential relevance to the ECM proteins (COL4A1, COL6A5, FN1, GP1BA, ITGA4, THBS3, and THBS4), and downregulation of apoptosis correlated proteins (BCL2, BCL2L1, CASP3, CASP7, and CDKN2A), suggesting the synergistic efficacy of PI3K-AKT inhibitor combined with anti-HER2 targeted agents.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259 · cited 1×
“8E-11 MSI/MSS-sig high (93) MSI/MSS-sig low (86)”
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Cited by
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Potential of Copper and Copper Compounds for Anticancer Applications
Ji, P., Wang, P., Chen, H., Xu, Y., Ge, J., Tian, Z., & Yan, Z. (2023) · Pharmaceuticals · doi:10.3390/ph16020234 · Cited by 162
“About 80% of gastric cancer patients are diagnosed in the middle and advanced stages, which is very difficult to treat [57].”
BackgroundBottom-Up Proteomics: Advancements in Sample Preparation
Duong, V., & Lee, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065350 · Cited by 161
Tumour‐associated macrophages in gastric cancer: From function and mechanism to application
Li, J., Sun, J., Zeng, Z., Liu, Z., Ma, M., Zheng, Z., He, Y., & Kang, W. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1386 · Cited by 97
Matsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“Beyond these studies, many researchers have sought other surrogate molecular classifications of GC to detect biomarkers and validate therapeutic prediction based on various analyses, including epigenome, proteome, metabolome, immunity, and tumor mutational burden [56,72,79–87].”
BackgroundMethod
Metadata
- Authors
- Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., Wu, X., Wang, Y., Liu, Y., Qin, Z., Liu, Y., Qin, J., Song, Q., Zhang, X., Sujie, A., Huang, J., Liu, T., Shen, K., Zhao, J.-Y., Hou, Y., & Ding, C.
- Affiliations
- Fudan University (CN)
- Henan Normal University (CN)
- Shanghai Medical College of Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Liu, Tianshu
- Shen, Kuntang
- Zhao, Jian-Yuan
- Hou, Yingyong
- Ding, Chen
- ORCID
- Venue
- Nature Communications
- Published
- 2022-09-29
- Volume
- 13
- Issue
- 1
- Pages
- 5723-5723
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9522856
- OpenAlex
- W4297998181
- Cited by
- 80
- References
- 101
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 23 · 2023: 15
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-11-08)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Shanghai Science and Technology Development Foundation (19MC1911000)
- National Natural Science Foundation of China (31972933, 2018YFA0507501, 2016YFA0502500, 19MC1911000, 2017SHZDZX01, 31700682, 31770886)
- China Postdoctoral Science Foundation (2017SHZDZX01, 2020T130114, 2019M651268)
- Science and Technology Commission of Shanghai Municipality (2020YFE0201600, 2017SHZDZX01)
- National Key Research and Development Program of China (2017YFA0505102, 2020YFE0201600, 2016YFA0502500, 2018YFA0507501, 2017YFC0908404, 2018YFE0201603, 2017SHZDZX01, 2017YFA0505101)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- gastric cancer, proteomic profiling, chemotherapy response, targeted therapy, HER2-targeted therapy, trastuzumab, docetaxel, drug resistance, tumor subtypes, T cell receptor signaling, extracellular matrix, PI3K/Akt signaling, TKTL1, chemosensitivity, prognostic model, treatment response prediction
- MeSH terms
- Trastuzumab, Docetaxel, Humans, Receptors, Antigen, T-Cell, Stomach Neoplasms, Transketolase, Phosphatidylinositol 3-Kinases, Proteome, Proteomics, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. https://app.cochat.ai/papers/10.1038/s41467-022-33282-0
- The paper
- Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., Wu, X., Wang, Y., Liu, Y., Qin, Z., Liu, Y., Qin, J., Song, Q., Zhang, X., Sujie, A., . . . Ding, C. (2022). Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nature Communications. https://doi.org/10.1038/s41467-022-33282-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.